David Michael Gay

David Michael Gay serves as an Assistant Professor in the Lund Group at the Biotech Research and Innovation Centre (BRIC), part of the Faculty of Health and Medical Sciences at the University of Copenhagen. His research focuses on the molecular mechanisms underlying cancer development and progression, with particular emphasis on colorectal cancer.

Gay's research interests center on ribosome biology and its role in cancer. His work explores how ribosomal modifications and translational control mechanisms influence cancer cell behavior, metabolism, and response to therapeutic interventions. His investigations into metabolic profiling of colorectal cancer have revealed novel therapeutic targets, while his studies on ribosomal RNA modifications have illuminated their impact on cell fate decisions. His research bridges molecular biology, cancer metabolism, and translational medicine.

Analysis of Gay's publication record from 2021-2023 reveals a strong focus on the intersection of ribosome function, metabolic regulation, and cancer biology. His work demonstrates how ribosomal alterations impact cancer progression, particularly in colorectal cancer contexts. Several publications examine KRAS-mutant colorectal cancer models, identifying potential therapeutic vulnerabilities through metabolic and translational control mechanisms. His research shows increasing interdisciplinary collaboration across cancer biology, metabolism, and molecular signaling fields.

Gay collaborates extensively within the University of Copenhagen and with international research groups, particularly working with the Lund Group led by A.H. Lund and maintaining significant collaborations with the Sansom laboratory. His work has been recognized through multiple publications in high-impact journals including Nature Metabolism, Science, Nature Genetics, and Cancer Discovery, with several papers receiving notable attention from both scientific and mainstream media outlets.

Gay maintains his laboratory at BRIC (Ole Maaløes Vej 5, 2200 København N.) where his team investigates ribosome heterogeneity, translational control mechanisms, and their implications for cancer biology and therapeutic development. His research group forms part of the vibrant cancer research community at the University of Copenhagen, contributing to the institution's strong reputation in molecular oncology and translational cancer research.